HealthTheStreet2 days ago
Johnson & Johnson bets $1 billion on hard-to-treat cancer
6 min read
Johnson & Johnson agreed to acquire Firefly Bio, a privately held biotechnology startup, for $1 billion in cash. Firefly's crown jewel is a single piece of technology aimed at hard-to-treat cancers. The deal pumps fresh cash into one of the most watched sectors in health care.
Level
Hype check
Tap to vote and see what everyone thinks.
